Picture loading failed.

Anti-CD274 therapeutic antibody (Pre-made Durvalumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1��) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-159-1mg 1mg 3090
GMP-Bios-ab-159-10mg 10mg 21890
GMP-Bios-ab-159-100mg 100mg 148000
GMP-Bios-ab-159-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD274 therapeutic antibody (Pre-made Durvalumab biosimilar,Whole mAb)
INN Name Durvalumab
TargetCD274
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5xj4:HL/5x8m:BC
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesAdvaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine
Conditions ApprovedNon-small cell lung cancer;Urogenital cancer;Small cell lung cancer
Conditions ActiveBiliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer
Conditions DiscontinuedCNS cancer;Lymphoproliferative disorders;Thyroid cancer
Development Techna